MedTrace Logo

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

NCT06865144 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-07-02

No results posted yet for this study

Summary

The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.

Conditions

  • Primary Open Angle Glaucoma or Ocular Hypertension

Interventions

DRUG

Netarsudil ophthalmic solution 0.02%

Apply one drop in each eye every evening

DRUG

Artificial tears

Apply one drop in each eye every evening

Sponsors & Collaborators

  • Alcon, a Novartis Company

    collaborator INDUSTRY

  • Florida Eye Specialists

    collaborator UNKNOWN

  • East Coast Institute for Research

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2026-04-01
Completion
2026-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06865144 on ClinicalTrials.gov